Zenas BioPharma

Overview

Zenas BioPharma is a biopharmaceutical company founded in 2021, with headquarters in Hong Kong and Boston. The company is dedicated to developing and commercializing innovative immune-based therapies for autoimmune and rare diseases. Zenas aims to become a global leader in this field, focusing on transformative therapies that address significant unmet medical needs.

The organization is advancing two late-stage franchises: Obexelimab, an investigational monoclonal antibody targeting B cell activity in autoimmune diseases, and Orelabrutinib, a selective oral small molecule BTK inhibitor for progressive multiple sclerosis and other indications. It also maintains a robust pipeline of earlier-stage programs, including several candidates with first-in-class potential for various autoimmune conditions. Zenas emphasizes operational excellence and innovation in its drug development process, spanning IND-enabling studies to global clinical trials and commercialization. The company collaborates with partners to expand its pipeline and enhance its impact on patients and the healthcare ecosystem.

Basic Information

Contact Details

• Phone: +1 857-271-2954
• Website: zenasbio.com
• LinkedIn: linkedin.com/company/zenas-biopharma

Key Focus Areas & Initiatives

• Autoimmune and rare disease therapy development
• Obexelimab monoclonal antibody research
• Orelabrutinib BTK inhibitor advancement
• First-in-class potential drug candidates
• Global clinical trials and drug commercialization
• Innovation in immune-based therapies
• Collaborations with healthcare partners
• Transformative therapies for unmet medical needs
• Pipeline expansion and operational excellence

Technologies Used

• AI
• Adobe Marketing Cloud
• Barracuda Networks
• Data Analytics
• IoT
• Microsoft Office 365
• Outlook
• Remote